Category: Cellectis

PharmaShots Weekly Snapshots (May 10 – 14, 2021)

Allergan Aesthetics, Amgen, Antengene, AstraZeneca, Aurinia, Bayer, Biogen, BioNTech, Cellectis, Dr. Reddy, Fulcrum Therapeutics, Goldfinch Bio, Heron Therapeutics, Incyte, InflaRx, Lilly, Medtronic, MiNA Therapeutics, MorphoSys, Nanobiotix, Novo Nordisk, Pfizer, Regeneron, Reistone, Sanofi, Soliton, TMS, Weekly Snapshot / May 14, 2021 May 14, 2021

AzurRx BioPharma Reports Positive Interim P-II Data of MS1819 + PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency Published: May 14, 2021 | Tags: AzurRx BioPharma, P-II, MS1819, PERT, Cystic Fibrosis, Severe, Exocrine Pancreatic Insufficiency Goldfinch Bio Initiates P-I Clinical Trial of GFB-024 for the Treatment of Severe Insulin Resistant Diabetic Nephropathy Published: …

PharmaShots Weekly Snapshots (May 10 – 14, 2021) Read More »

Cellectis Collaborates with Sanofi for Alemtuzumab to be Utilized in CART-Cell Trials

Alemtuzumab, All, AML, Biotech, Cellectis, Sanofi, UCART123, UCART22 / May 12, 2021 May 12, 2021

Shots: The companies enter into a supply agreement for Alemtuzumab to be used in Cellectis’ trials as a lymphodepleting regimen for UCART22 in the BALLI-01 clinical trial to treat r/r ALL, and for UCART123 in AMELI-01 clinical trial to treat r/r AML but not for UCARTCS1 due to self-lymphodepleting activity Sanofi will provide alemtuzumab for …

Cellectis Collaborates with Sanofi for Alemtuzumab to be Utilized in CART-Cell Trials Read More »

FDA slaps hold on Cellectis’ off-the-shelf myeloma CAR-T trial after patient death

BioPharma, biopharma nl, cancer, CAR-T, cell therapy, Cellectis, Daily, Food and Drug Administration, France, multiple myeloma, Paris, SYN, Top Story / July 7, 2020 July 7, 2020

The patient, who had been enrolled in the Phase I study at the higher dose level of UCARTCS1A, suffered a cardiac arrest, the causes of which are under investigation, the company said.